A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.

@article{Dell1998ARD,
  title={A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis.},
  author={Steven J. Dell and Genevieve Lowry and J A Northcutt and Jonathan B. Howes and Gary D. Novack and K. Lenore Hart},
  journal={The Journal of allergy and clinical immunology},
  year={1998},
  volume={102 2},
  pages={251-5}
}
BACKGROUND Loteprednol etabonate is a site-active corticosteroid with efficacy and safety in treating ocular inflammation at the 0.5% concentration. Evidence from dose-response studies suggested that the 0.2% concentration might be effective in treating ocular allergy. OBJECTIVES The objective of this study was to evaluate the effects of 0.2% loteprednol etabonate in reducing the signs and symptoms of seasonal allergic conjunctivitis. METHODS This was a randomized, double-masked, placebo… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Similar Papers

Loading similar papers…